Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
Status:
Recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
This study will compare ofatumumab vs. European approved platform first line
self-administered disease modifying therapy (DMT) in newly diagnosed MS patients